Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer
- Kevin M. Harter, former Saladax Executive Chairman, Named Interim CEO-
Bethlehem, PA, January 27, 2012
– Saladax Biomedical, Inc., a privately-held company developing and
commercializing novel diagnostic assays to achieve the promise of
personalized medicine for new and existing therapeutics, announced today
that Edward L. Erickson, its President and Chief Executive Officer, has
resigned due to personal family reasons. His resignation will be
effective as an executive officer of Saladax on February 12, 2012, but
he will remain a member of the company’s board of directors.
Kevin M. Harter, who is a co-founder and Senior Vice President of the
Life Science Greenhouse, a public-private partnership, has been named
interim CEO. From 2007 to 2011, Mr. Harter also served as Executive
Chairman of Saladax Biomedical, a Life Science Greenhouse portfolio
company, where he led successful funding rounds and strategic alliances
for the company.
Gregory Critchfield, M.D., Chairman of the Board at Saladax,
commented, “The board of directors wishes to express its sincere thanks
for Ed’s work, his energy and his commitment in growing Saladax. We are
pleased that Ed will remain on the board of directors, as an advisor to
the company, with nearly three decades of relevant experience in
diagnostics, therapeutics and life science research.The board of
directors also extends its gratitude to Kevin for his willingness to
assist the company in this interim role. His skill, knowledge and
leadership will be invaluable to Saladax.”
Dr. Critchfield continued, “The board of directors is initiating a
search to find a permanent CEO. This search will encompass looking
within and outside the company, to find the best candidate to continue
to execute the company’s strategy and to achieve its promise to become a
major provider of personalized medicine products to the medical
community for the betterment of patient care.”
About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic
assays to achieve the promise of personalized medicine through dose
management and companion diagnostic products for existing and new
therapeutics. The Company’s dose management technology enables
physicians to optimize drug dosing to meet individual patient needs,
leading to improved response and quality of life. The Company’s 15
MyCare™ dose management assays are comprised of proprietary, automated
and cost-effective in vitro diagnostic tests, with a principal
focus in oncology. The first MyCare assay available is for one of the
most common anticancer drugs, 5-fluorouracil (5-FU). This assay is sold
by Saladax in Europe as a CE-marked product and will be distributed in
Japan by FALCO biosystems. In the United States and Canada, Myriad
Genetic Laboratories, Inc. provides testing for 5-FU dose optimization
under the trademark OnDose® through a license to Saladax
proprietary technology. In addition the company is finalizing
development of its next two oncology drug assays for paclitaxel and
docetaxel. Saladax also works with pharmaceutical companies to develop
companion diagnostics to provide important clinical information to
assist in developing and administering new and existing compounds. For
more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.
Media Contact:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
or
Jason Rando
moc.dnerebit@odnarj
No comments:
Post a Comment